Closed · RFA-DA-25-058 · CFDA 93.279 · Discretionary
Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $2M
- Award range
- Closed
- Status
- February 28, 2024
- Close date
- -
- Expected awards
The verdict
Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $2,000,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $2M
- award range
- Closed
- application status
- 93.279
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Psychedelics Treatment Research in Substance… is closed (last close February 28, 2024). The parent program page for CFDA 93.279 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed February 28, 2024
Instrument
Cooperative Agreement
Description
Psychedelic treatments are currently in clinical development for a range of mental disorders. Therapeutic areas undergoing active clinical research include alcohol and substance use disorders (ASUD). The exploration of the beneficial clinical and functional outcomes require our urgent attention to the refinement and optimization of the psychedelic treatment administration paradigms, and an exploration of novel clinical trial designs, which are of high nascent interest for the ASUD field in general. This Concept supports clinical studies applications to study psychedelic treatment administration paradigms, assess the role of psychotherapy in its administration, and describe and assess the range of clinical outcomes, including downstream functional effects, that are evidenced as the result of this treatment
Wide-open applicant board · 15 Grants.gov doors
Psychedelics Treatment Research in Substance… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 05
- Independent school districts
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH Grants Information grantsinfo@nih.gov
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Psychedelics Treatment Research in Substance… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.279 may publish future NOFOs under the same assistance listing. Open program
- Drug Abuse Research Programs indexes 170 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |